Clinical Adoption of Advanced Therapies: Challenges and Opportunities

As the cell and gene therapy field matures the powerful therapeutic potential of these innovative therapies is starting to be shown, particularly in the fields of oncology and childhood immune deficiency diseases. However, as more therapies enter late stage clinical trials, advances and innovation are required in manufacturing, logistics, regulation, reimbursement and the healthcare setting to ensure that systems are in place to support wider clinical adoption of these promising treatments. A window of opportunity exists to implement new methodologies for best practice in both the ability to manufacture products reproducibly at scale, as well as ensuring healthcare systems are not overwhelmed by the variety and complexity of these new therapies and the additional burden they will place on already stretched facilities. If all interested parties work together it will be possible for the sector to develop the necessary processes, skilled staff and infrastructure needed as more treatments move from clinical trial to marketed products. (C) 2020 American Pharmacists Association?. Published by Elsevier Inc. All rights reserved.

Automated summary

With the maturing of the cell and gene therapy field, advancements in manufacturing, logistics, regulation, reimbursement, and healthcare facilities are necessary to support the wider clinical adoption of promising treatments. Collaboration among stakeholders is crucial to develop the required processes, skilled workforce, and infrastructure needed for the transition of more treatments from clinical trials to marketed products.